Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Curcumin Nanoformulations for Colorectal Cancer: A Review.

Wong KE, Ngai SC, Chan KG, Lee LH, Goh BH, Chuah LH.

Front Pharmacol. 2019 Mar 5;10:152. doi: 10.3389/fphar.2019.00152. eCollection 2019. Review.

2.

Enhancing Curcumin Oral Bioavailability Through Nanoformulations.

Ipar VS, Dsouza A, Devarajan PV.

Eur J Drug Metab Pharmacokinet. 2019 Feb 15. doi: 10.1007/s13318-019-00545-z. [Epub ahead of print]

PMID:
30771095
3.

Curcumin nanoformulations: a future nanomedicine for cancer.

Yallapu MM, Jaggi M, Chauhan SC.

Drug Discov Today. 2012 Jan;17(1-2):71-80. doi: 10.1016/j.drudis.2011.09.009. Epub 2011 Sep 18. Review.

4.

Multifunctional polymeric nanocurcumin for cancer therapy.

Shehzad A, Ul-Islam M, Wahid F, Lee YS.

J Nanosci Nanotechnol. 2014 Jan;14(1):803-14. Review.

PMID:
24730299
5.

Curcumin nanoformulations: a review of pharmaceutical properties and preclinical studies and clinical data related to cancer treatment.

Naksuriya O, Okonogi S, Schiffelers RM, Hennink WE.

Biomaterials. 2014 Mar;35(10):3365-83. doi: 10.1016/j.biomaterials.2013.12.090. Epub 2014 Jan 15. Review.

PMID:
24439402
6.

Cellular uptake and anticancer effects of mucoadhesive curcumin-containing chitosan nanoparticles.

Chuah LH, Roberts CJ, Billa N, Abdullah S, Rosli R.

Colloids Surf B Biointerfaces. 2014 Apr 1;116:228-36. doi: 10.1016/j.colsurfb.2014.01.007. Epub 2014 Jan 15.

PMID:
24486834
7.

Liposomal curcumin and its application in cancer.

Feng T, Wei Y, Lee RJ, Zhao L.

Int J Nanomedicine. 2017 Aug 21;12:6027-6044. doi: 10.2147/IJN.S132434. eCollection 2017. Review.

8.

Hansen solubility parameters (HSP) for prescreening formulation of solid lipid nanoparticles (SLN): in vitro testing of curcumin-loaded SLN in MCF-7 and BT-474 cell lines.

Doktorovova S, Souto EB, Silva AM.

Pharm Dev Technol. 2018 Jan;23(1):96-105. doi: 10.1080/10837450.2017.1384491. Epub 2017 Oct 10.

PMID:
28949267
9.

Therapeutic Applications of Curcumin Nanoformulations.

Yallapu MM, Nagesh PK, Jaggi M, Chauhan SC.

AAPS J. 2015 Nov;17(6):1341-56. doi: 10.1208/s12248-015-9811-z. Epub 2015 Sep 3. Review.

10.

Polyphenol nanoformulations for cancer therapy: experimental evidence and clinical perspective.

Davatgaran-Taghipour Y, Masoomzadeh S, Farzaei MH, Bahramsoltani R, Karimi-Soureh Z, Rahimi R, Abdollahi M.

Int J Nanomedicine. 2017 Apr 4;12:2689-2702. doi: 10.2147/IJN.S131973. eCollection 2017. Review.

11.

Recent progress in studying curcumin and its nano-preparations for cancer therapy.

Liu J, Chen S, Lv L, Song L, Guo S, Huang S.

Curr Pharm Des. 2013;19(11):1974-93. Review.

PMID:
23116308
12.

Plasma proteins interaction with curcumin nanoparticles: implications in cancer therapeutics.

Yallapu MM, Ebeling MC, Jaggi M, Chauhan SC.

Curr Drug Metab. 2013 May;14(4):504-15. Review.

13.

Recent advances in curcumin nanoformulation for cancer therapy.

Lee WH, Loo CY, Young PM, Traini D, Mason RS, Rohanizadeh R.

Expert Opin Drug Deliv. 2014 Aug;11(8):1183-201. doi: 10.1517/17425247.2014.916686. Epub 2014 May 24. Review.

PMID:
24857605
14.

Advances in nanotechnology-based delivery systems for curcumin.

Sun M, Su X, Ding B, He X, Liu X, Yu A, Lou H, Zhai G.

Nanomedicine (Lond). 2012 Jul;7(7):1085-100. doi: 10.2217/nnm.12.80. Review.

PMID:
22846093
15.

Progress in nanotechnology-based drug carrier in designing of curcumin nanomedicines for cancer therapy: current state-of-the-art.

Ahmad MZ, Alkahtani SA, Akhter S, Ahmad FJ, Ahmad J, Akhtar MS, Mohsin N, Abdel-Wahab BA.

J Drug Target. 2016;24(4):273-93. doi: 10.3109/1061186X.2015.1055570. Epub 2015 Jun 11. Review.

PMID:
26066739
16.

Nanotechnology-applied curcumin for different diseases therapy.

Ghalandarlaki N, Alizadeh AM, Ashkani-Esfahani S.

Biomed Res Int. 2014;2014:394264. doi: 10.1155/2014/394264. Epub 2014 Jun 5. Review.

17.

Development of Curcumin-Loaded Solid Lipid Nanoparticles Utilizing Glyceryl Monostearate as Single Lipid Using QbD Approach: Characterization and Evaluation of Anticancer Activity Against Human Breast Cancer Cell Line.

Bhatt H, Rompicharla SVK, Komanduri N, Aashma S, Paradkar S, Ghosh B, Biswas S.

Curr Drug Deliv. 2018;15(9):1271-1283. doi: 10.2174/1567201815666180503120113.

PMID:
29732970
18.

Interaction of curcumin nanoformulations with human plasma proteins and erythrocytes.

Yallapu MM, Ebeling MC, Chauhan N, Jaggi M, Chauhan SC.

Int J Nanomedicine. 2011;6:2779-90. doi: 10.2147/IJN.S25534. Epub 2011 Nov 8.

19.

Oral bioavailability of curcumin: problems and advancements.

Liu W, Zhai Y, Heng X, Che FY, Chen W, Sun D, Zhai G.

J Drug Target. 2016 Sep;24(8):694-702. doi: 10.3109/1061186X.2016.1157883. Epub 2016 Mar 17. Review.

PMID:
26942997
20.

Surface modification of solid lipid nanoparticles for oral delivery of curcumin: Improvement of bioavailability through enhanced cellular uptake, and lymphatic uptake.

Baek JS, Cho CW.

Eur J Pharm Biopharm. 2017 Aug;117:132-140. doi: 10.1016/j.ejpb.2017.04.013. Epub 2017 Apr 12.

PMID:
28412471

Supplemental Content

Support Center